Simultaneous Quantification of Apolipoprotein A-I and Apolipoprotein B by Liquid-Chromatography–Multiple- Reaction–Monitoring Mass Spectrometry
Open Access
- 1 December 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 56 (12) , 1804-1813
- https://doi.org/10.1373/clinchem.2010.152264
Abstract
BACKGROUND: If liquid-chromatography–multiple-reaction–monitoring mass spectrometry (LC-MRM/MS) could be used in the large-scale preclinical verification of putative biomarkers, it would obviate the need for the development of expensive immunoassays. In addition, the translation of novel biomarkers to clinical use would be accelerated if the assays used in preclinical studies were the same as those used in the clinical laboratory. To validate this approach, we developed a multiplexed assay for the quantification of 2 clinically well-known biomarkers in human plasma, apolipoprotein A-I and apolipoprotein B (apoA-I and apoB). METHODS: We used PeptideAtlas to identify candidate peptides. Human samples were denatured with urea or trifluoroethanol, reduced and alkylated, and digested with trypsin. We compared reversed-phase chromatographic separation of peptides with normal flow and microflow, and we normalized endogenous peptide peak areas to internal standard peptides. We evaluated different methods of calibration and compared the final method with a nephelometric immunoassay. RESULTS: We developed a final method using trifluoroethanol denaturation, 21-h digestion, normal flow chromatography-electrospray ionization, and calibration with a single normal human plasma sample. For samples injected in duplicate, the method had intraassay CVs <6% and interassay CVs <12% for both proteins, and compared well with immunoassay (n = 47; Deming regression, LC-MRM/MS = 1.17 × immunoassay − 36.6; Sx|y = 10.3 for apoA-I and LC-MRM/MS = 1.21 × immunoassay + 7.0; Sx|y = 7.9 for apoB). CONCLUSIONS: Multiplexed quantification of proteins in human plasma/serum by LC-MRM/MS is possible and compares well with clinically useful immunoassays. The potential application of single-point calibration to large clinical studies could simplify efforts to reduce day-to-day digestion variability.Funding Information
- University of Washington
This publication has 37 references indexed in Scilit:
- An Automated and Multiplexed Method for High Throughput Peptide Immunoaffinity Enrichment and Multiple Reaction Monitoring Mass Spectrometry-based Quantification of Protein BiomarkersMolecular & Cellular Proteomics, 2010
- Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteinsJournal of Lipid Research, 2009
- Multiple Reaction Monitoring-based, Multiplexed, Absolute Quantitation of 45 Proteins in Human PlasmaMolecular & Cellular Proteomics, 2009
- Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasmaNature Biotechnology, 2009
- The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometryJournal of Immunological Methods, 2009
- Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass SpectrometryClinical Chemistry, 2009
- A Human Proteome Detection and Quantitation ProjectMolecular & Cellular Proteomics, 2009
- Protein Quantitation through Targeted Mass Spectrometry: The Way Out of Biomarker Purgatory?Clinical Chemistry, 2008
- Quantification of Thyroglobulin, a Low-Abundance Serum Protein, by Immunoaffinity Peptide Enrichment and Tandem Mass SpectrometryClinical Chemistry, 2008
- The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipelineProteomics – Clinical Applications, 2008